Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Tvardi Therapeutics, Inc.TVRD · Entity 7579 | Director | June 09, 2026 | June 11, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Tvardi Therapeutics, Inc.
Report date June 09, 2026 · Filed June 11, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.78 · Expires 2036-06-08 | Direct | 6,000 |
Reported balance
After 2026-06-09 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-09 · Grant · Acquired 6,000 · Balance 6,000 F1: 100% of the shares underlying the option shall vest on the earlier of June 9, 2027 or the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continuous service through such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: 100% of the shares underlying the option shall vest on the earlier of June 9, 2027 or the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continuous service through such vesting date.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
CymaBay Therapeutics, Inc.
Report date March 22, 2024 · Filed March 22, 2024
Section 16 reporting ended · disclosed 2024-03-22. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2024-03-22 transaction · row 1
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 1 · 2024-03-22 · Disposition to issuer · Disposed 310,420 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated as of February 11, 2024 (the "Merger Agreement"), by and among CymaBay Therapeutics, Inc. ("CymaBay"), Gilead Sciences, Inc., a Delaware corporation ("Gilead"), and Pacific Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Gilead ("Purchaser"), among other things, Purchaser merged with and into the Company (the "Merger"). Accordingly, each outstanding share of CymaBay common stock was converted into the right to receive a cash payment equal to $32.50, less applicable withholding taxes. |
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2024-03-22 transaction · row 2
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 2 · 2024-03-22 · Disposition to issuer · Disposed 96,250 · Balance 0 F2: Pursuant to the Merger Agreement, each outstanding CymaBay restricted stock unit award was cancelled and converted into the right to receive a cash payment equal to the product of (i) the number of shares of CymaBay common stock subject to such restricted stock unit award and (ii) $32.50, less applicable withholding taxes. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.00 · Expires 2025-01-06 | Direct | 0 |
Reported balance
After 2024-03-22 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2024-03-22 · Disposition to issuer · Disposed 88,351 · Balance 0 F3: Pursuant to the Merger Agreement, each outstanding CymaBay stock option, whether or not vested, was cancelled and converted into the right to receive a cash payment equal to the product of (a) the excess of (i) $32.50 over (ii) the per share exercise price of such stock option, and (b) the total number of shares of CymaBay common stock subject to such stock option immediately prior to the effective time of the Merger, less applicable withholding taxes. Any outstanding CymaBay stock option with an exercise price equal to or greater than $32.50 was canceled for no consideration. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.06 · Expires 2026-01-25 | Direct | 0 |
Reported balance
After 2024-03-22 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2024-03-22 · Disposition to issuer · Disposed 39,375 · Balance 0 F3: Pursuant to the Merger Agreement, each outstanding CymaBay stock option, whether or not vested, was cancelled and converted into the right to receive a cash payment equal to the product of (a) the excess of (i) $32.50 over (ii) the per share exercise price of such stock option, and (b) the total number of shares of CymaBay common stock subject to such stock option immediately prior to the effective time of the Merger, less applicable withholding taxes. Any outstanding CymaBay stock option with an exercise price equal to or greater than $32.50 was canceled for no consideration. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.82 · Expires 2026-07-24 | Direct | 0 |
Reported balance
After 2024-03-22 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2024-03-22 · Disposition to issuer · Disposed 50,000 · Balance 0 F3: Pursuant to the Merger Agreement, each outstanding CymaBay stock option, whether or not vested, was cancelled and converted into the right to receive a cash payment equal to the product of (a) the excess of (i) $32.50 over (ii) the per share exercise price of such stock option, and (b) the total number of shares of CymaBay common stock subject to such stock option immediately prior to the effective time of the Merger, less applicable withholding taxes. Any outstanding CymaBay stock option with an exercise price equal to or greater than $32.50 was canceled for no consideration. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.72 · Expires 2027-01-18 | Direct | 0 |
Reported balance
After 2024-03-22 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2024-03-22 · Disposition to issuer · Disposed 47,916 · Balance 0 F3: Pursuant to the Merger Agreement, each outstanding CymaBay stock option, whether or not vested, was cancelled and converted into the right to receive a cash payment equal to the product of (a) the excess of (i) $32.50 over (ii) the per share exercise price of such stock option, and (b) the total number of shares of CymaBay common stock subject to such stock option immediately prior to the effective time of the Merger, less applicable withholding taxes. Any outstanding CymaBay stock option with an exercise price equal to or greater than $32.50 was canceled for no consideration. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.48 · Expires 2027-04-26 | Direct | 0 |
Reported balance
After 2024-03-22 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2024-03-22 · Disposition to issuer · Disposed 90,000 · Balance 0 F3: Pursuant to the Merger Agreement, each outstanding CymaBay stock option, whether or not vested, was cancelled and converted into the right to receive a cash payment equal to the product of (a) the excess of (i) $32.50 over (ii) the per share exercise price of such stock option, and (b) the total number of shares of CymaBay common stock subject to such stock option immediately prior to the effective time of the Merger, less applicable withholding taxes. Any outstanding CymaBay stock option with an exercise price equal to or greater than $32.50 was canceled for no consideration. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.21 · Expires 2027-10-26 | Direct | 0 |
Reported balance
After 2024-03-22 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2024-03-22 · Disposition to issuer · Disposed 621,101 · Balance 0 F3: Pursuant to the Merger Agreement, each outstanding CymaBay stock option, whether or not vested, was cancelled and converted into the right to receive a cash payment equal to the product of (a) the excess of (i) $32.50 over (ii) the per share exercise price of such stock option, and (b) the total number of shares of CymaBay common stock subject to such stock option immediately prior to the effective time of the Merger, less applicable withholding taxes. Any outstanding CymaBay stock option with an exercise price equal to or greater than $32.50 was canceled for no consideration. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.69 · Expires 2028-01-23 | Direct | 0 |
Reported balance
After 2024-03-22 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2024-03-22 · Disposition to issuer · Disposed 146,875 · Balance 0 F3: Pursuant to the Merger Agreement, each outstanding CymaBay stock option, whether or not vested, was cancelled and converted into the right to receive a cash payment equal to the product of (a) the excess of (i) $32.50 over (ii) the per share exercise price of such stock option, and (b) the total number of shares of CymaBay common stock subject to such stock option immediately prior to the effective time of the Merger, less applicable withholding taxes. Any outstanding CymaBay stock option with an exercise price equal to or greater than $32.50 was canceled for no consideration. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.43 · Expires 2029-01-28 | Direct | 0 |
Reported balance
After 2024-03-22 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2024-03-22 · Disposition to issuer · Disposed 314,120 · Balance 0 F3: Pursuant to the Merger Agreement, each outstanding CymaBay stock option, whether or not vested, was cancelled and converted into the right to receive a cash payment equal to the product of (a) the excess of (i) $32.50 over (ii) the per share exercise price of such stock option, and (b) the total number of shares of CymaBay common stock subject to such stock option immediately prior to the effective time of the Merger, less applicable withholding taxes. Any outstanding CymaBay stock option with an exercise price equal to or greater than $32.50 was canceled for no consideration. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.05 · Expires 2030-05-14 | Direct | 0 |
Reported balance
After 2024-03-22 transaction · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · 2024-03-22 · Disposition to issuer · Disposed 536,032 · Balance 0 F3: Pursuant to the Merger Agreement, each outstanding CymaBay stock option, whether or not vested, was cancelled and converted into the right to receive a cash payment equal to the product of (a) the excess of (i) $32.50 over (ii) the per share exercise price of such stock option, and (b) the total number of shares of CymaBay common stock subject to such stock option immediately prior to the effective time of the Merger, less applicable withholding taxes. Any outstanding CymaBay stock option with an exercise price equal to or greater than $32.50 was canceled for no consideration. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.78 · Expires 2031-01-25 | Direct | 0 |
Reported balance
After 2024-03-22 transaction · row 12
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 12 · 2024-03-22 · Disposition to issuer · Disposed 284,712 · Balance 0 F3: Pursuant to the Merger Agreement, each outstanding CymaBay stock option, whether or not vested, was cancelled and converted into the right to receive a cash payment equal to the product of (a) the excess of (i) $32.50 over (ii) the per share exercise price of such stock option, and (b) the total number of shares of CymaBay common stock subject to such stock option immediately prior to the effective time of the Merger, less applicable withholding taxes. Any outstanding CymaBay stock option with an exercise price equal to or greater than $32.50 was canceled for no consideration. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.94 · Expires 2032-01-24 | Direct | 0 |
Reported balance
After 2024-03-22 transaction · row 13
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 13 · 2024-03-22 · Disposition to issuer · Disposed 649,999 · Balance 0 F3: Pursuant to the Merger Agreement, each outstanding CymaBay stock option, whether or not vested, was cancelled and converted into the right to receive a cash payment equal to the product of (a) the excess of (i) $32.50 over (ii) the per share exercise price of such stock option, and (b) the total number of shares of CymaBay common stock subject to such stock option immediately prior to the effective time of the Merger, less applicable withholding taxes. Any outstanding CymaBay stock option with an exercise price equal to or greater than $32.50 was canceled for no consideration. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.80 · Expires 2033-01-24 | Direct | 0 |
Reported balance
After 2024-03-22 transaction · row 14
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 14 · 2024-03-22 · Disposition to issuer · Disposed 800,000 · Balance 0 F3: Pursuant to the Merger Agreement, each outstanding CymaBay stock option, whether or not vested, was cancelled and converted into the right to receive a cash payment equal to the product of (a) the excess of (i) $32.50 over (ii) the per share exercise price of such stock option, and (b) the total number of shares of CymaBay common stock subject to such stock option immediately prior to the effective time of the Merger, less applicable withholding taxes. Any outstanding CymaBay stock option with an exercise price equal to or greater than $32.50 was canceled for no consideration. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $22.85 · Expires 2034-01-23 | Direct | 0 |
Reported balance
After 2024-03-22 transaction · row 15
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 15 · 2024-03-22 · Disposition to issuer · Disposed 357,500 · Balance 0 F3: Pursuant to the Merger Agreement, each outstanding CymaBay stock option, whether or not vested, was cancelled and converted into the right to receive a cash payment equal to the product of (a) the excess of (i) $32.50 over (ii) the per share exercise price of such stock option, and (b) the total number of shares of CymaBay common stock subject to such stock option immediately prior to the effective time of the Merger, less applicable withholding taxes. Any outstanding CymaBay stock option with an exercise price equal to or greater than $32.50 was canceled for no consideration. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the Agreement and Plan of Merger, dated as of February 11, 2024 (the "Merger Agreement"), by and among CymaBay Therapeutics, Inc. ("CymaBay"), Gilead Sciences, Inc., a Delaware corporation ("Gilead"), and Pacific Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Gilead ("Purchaser"), among other things, Purchaser merged with and into the Company (the "Merger"). Accordingly, each outstanding share of CymaBay common stock was converted into the right to receive a cash payment equal to $32.50, less applicable withholding taxes.
F2: Pursuant to the Merger Agreement, each outstanding CymaBay restricted stock unit award was cancelled and converted into the right to receive a cash payment equal to the product of (i) the number of shares of CymaBay common stock subject to such restricted stock unit award and (ii) $32.50, less applicable withholding taxes.
F3: Pursuant to the Merger Agreement, each outstanding CymaBay stock option, whether or not vested, was cancelled and converted into the right to receive a cash payment equal to the product of (a) the excess of (i) $32.50 over (ii) the per share exercise price of such stock option, and (b) the total number of shares of CymaBay common stock subject to such stock option immediately prior to the effective time of the Merger, less applicable withholding taxes. Any outstanding CymaBay stock option with an exercise price equal to or greater than $32.50 was canceled for no consideration.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| November 13, 2023 Filed Nov 14, 2023 18:00 UTC | CymaBay Therapeutics, Inc. CBAY · Entity 92768 | Exercise / conversionCommon Stock | 20,855 | $5.00 | $104,275.00 |
DisclosureSEC source: 0001062993-23-020835 · form4.xml · nonDerivative · entry 3 Shah Sujal · CIK 0001588861 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 192,156 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 13, 2023 Filed Nov 14, 2023 18:00 UTC | CymaBay Therapeutics, Inc. CBAY · Entity 92768 | SaleCommon Stock | 44,008 | $15.89 | $699,309.12 |
DisclosureSEC source: 0001062993-23-020835 · form4.xml · nonDerivative · entry 2 Shah Sujal · CIK 0001588861 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 171,301 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into on June 28, 2023. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.54 to $16.28, inclusive. The reporting person undertakes to provide to CymaBay Therapeutics, Inc., any security holder of CymaBay Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 13, 2023 Filed Nov 14, 2023 18:00 UTC | CymaBay Therapeutics, Inc. CBAY · Entity 92768 | Exercise / conversionCommon Stock | 44,008 | $5.00 | $220,040.00 |
DisclosureSEC source: 0001062993-23-020835 · form4.xml · nonDerivative · entry 1 Shah Sujal · CIK 0001588861 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 215,309 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 09, 2023 Filed Oct 10, 2023 17:04 UTC | CymaBay Therapeutics, Inc. CBAY · Entity 92768 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 20,855 | $0.00 Strike: $5.00 | $0.00 |
DisclosureSEC source: 0001062993-23-019205 · form4.xml · derivative · entry 5 Shah Sujal · CIK 0001588861 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 41,711 Underlying: Common Stock · 20,855 shares Expires 2024-01-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The option vested over a four-year period, with one-third of the shares subject to the Option vesting on the grant date of January 6, 2014, and the remaining 2/3 of the shares subject to the Option vesting ratably on a monthly basis over the 48 months. Read SEC document |
| October 09, 2023 Filed Oct 10, 2023 17:04 UTC | CymaBay Therapeutics, Inc. CBAY · Entity 92768 | Exercise / conversionStock Appreciation Right · Derivative | 12,972 | $0.00 Strike: $5.00 | $0.00 |
DisclosureSEC source: 0001062993-23-019205 · form4.xml · derivative · entry 4 Shah Sujal · CIK 0001588861 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 25,945 Underlying: Common Stock · 12,972 shares Expires 2023-12-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The award was granted under the CymaBay 2013 Equity Incentive Plan and can be settled in cash or shares of CymaBay common stock, at the sole discretion of CymaBay. The award vested in full on the two-year anniversary of the grant date. Read SEC document |
| October 09, 2023 Filed Oct 10, 2023 17:04 UTC | CymaBay Therapeutics, Inc. CBAY · Entity 92768 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 31,034 | $0.00 Strike: $5.00 | $0.00 |
DisclosureSEC source: 0001062993-23-019205 · form4.xml · derivative · entry 3 Shah Sujal · CIK 0001588861 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 62,072 Underlying: Common Stock · 31,034 shares Expires 2023-12-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The option vested over a four-year period, with one-third of the shares subject to the option vesting on the grant date of December 23, 2013, and the remaining 2/3 of the shares subject to the option vesting ratably on a monthly basis over the 48 months thereafter. Read SEC document |
| October 09, 2023 Filed Oct 10, 2023 17:04 UTC | CymaBay Therapeutics, Inc. CBAY · Entity 92768 | SaleCommon Stock | 64,861 | $14.20 | $921,285.64 |
DisclosureSEC source: 0001062993-23-019205 · form4.xml · nonDerivative · entry 2 Shah Sujal · CIK 0001588861 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 171,301 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into on June 28, 2023. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.07 to $14.35, inclusive. The reporting person undertakes to provide to CymaBay Therapeutics, Inc., any security holder of CymaBay Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| October 09, 2023 Filed Oct 10, 2023 17:04 UTC | CymaBay Therapeutics, Inc. CBAY · Entity 92768 | Exercise / conversionCommon Stock | 64,861 | $5.00 | $324,305.00 |
DisclosureSEC source: 0001062993-23-019205 · form4.xml · nonDerivative · entry 1 Shah Sujal · CIK 0001588861 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 236,162 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 25, 2023 Filed Jan 27, 2023 16:27 UTC | CymaBay Therapeutics, Inc. CBAY · Entity 92768 | GrantEmployee Stock Option (right to buy) · Derivative | 800,000 | $0.00 Strike: $7.80 | $0.00 |
DisclosureSEC source: 0001062993-23-001493 · form4.xml · derivative · entry 1 Shah Sujal · CIK 0001588861 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 800,000 Underlying: Common Stock · 800,000 shares Expires 2033-01-24 F1 · derivative.exercise_date: The option vests as to 1/48 of the underlying shares monthly from January 1, 2023. Read SEC document |
| June 06, 2022 Filed Jun 7, 2022 08:14 UTC | CymaBay Therapeutics, Inc. CBAY · Entity 92768 | PurchaseCommon Stock | 51,301 | $1.95 | $100,036.95 |
DisclosureSEC source: 0001062993-22-014432 · form4.xml · nonDerivative · entry 1 Shah Sujal · CIK 0001588861 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 171,301 Read SEC document |
| January 25, 2022 Filed Jan 27, 2022 16:55 UTC | CymaBay Therapeutics, Inc. CBAY · Entity 92768 | GrantEmployee Stock Option (right to buy) · Derivative | 650,000 | $0.00 Strike: $2.94 | $0.00 |
DisclosureSEC source: 0001062993-22-001697 · form4.xml · derivative · entry 1 Shah Sujal · CIK 0001588861 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 650,000 Underlying: Common Stock · 650,000 shares Expires 2032-01-24 F1 · derivative.exercise_date: The option vests as to 1/48 of the underlying shares monthly from January 1, 2022. Read SEC document |
| January 26, 2021 Filed Jan 28, 2021 14:56 UTC | CymaBay Therapeutics, Inc. CBAY · Entity 92768 | GrantEmployee Stock Option (right to buy) · Derivative | 287,000 | $0.00 Strike: $5.78 | $0.00 |
DisclosureSEC source: 0001333277-21-000020 · edgar.xml · derivative · entry 1 Shah Sujal · CIK 0001588861 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 287,000 Underlying: Common Stock · 287,000 shares Expires 2031-01-25 F1 · derivative.exercise_date: The option vests as to 1/48 of the underlying shares monthly from January 1, 2021. Read SEC document |
| May 15, 2020 Filed May 19, 2020 17:12 UTC | CymaBay Therapeutics, Inc. CBAY · Entity 92768 | GrantStock Option (Right to Buy) · Derivative | 558,108 | $0.00 Strike: $4.05 | $0.00 |
DisclosureSEC source: 0001209191-20-030579 · doc4.xml · derivative · entry 1 Shah Sujal · CIK 0001588861 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 558,108 Underlying: Common Stock · 558,108 shares Expires 2030-05-14 F1 · derivative.exercise_date: The shares subject to the option shall vest in 48 equal monthly installments commencing on January 31, 2020, subject to the Reporting Person's continuous service to the Issuer as of each such date. Read SEC document |
| October 10, 2019 Filed Oct 15, 2019 08:20 UTC | CymaBay Therapeutics, Inc. CBAY · Entity 92768 | PurchaseCommon Stock | 5,000 | $4.30 | $21,500.00 |
DisclosureSEC source: 0001333277-19-000046 · edgar.xml · nonDerivative · entry 1 Shah Sujal · CIK 0001588861 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 120,000 Read SEC document |
| September 23, 2019 Filed Sep 24, 2019 08:56 UTC | CymaBay Therapeutics, Inc. CBAY · Entity 92768 | PurchaseCommon Stock | 3,100 | $5.55 | $17,205.00 |
DisclosureSEC source: 0001333277-19-000044 · edgar.xml · nonDerivative · entry 2 Shah Sujal · CIK 0001588861 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 115,000 Read SEC document |
| September 20, 2019 Filed Sep 24, 2019 08:56 UTC | CymaBay Therapeutics, Inc. CBAY · Entity 92768 | PurchaseCommon Stock | 1,900 | $5.50 | $10,450.00 |
DisclosureSEC source: 0001333277-19-000044 · edgar.xml · nonDerivative · entry 1 Shah Sujal · CIK 0001588861 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 111,900 Read SEC document |
| January 29, 2019 Filed Jan 31, 2019 17:26 UTC | CymaBay Therapeutics, Inc. CBAY · Entity 92768 | GrantEmployee Stock Option (right to buy) · Derivative | 328,492 | $0.00 Strike: $8.43 | $0.00 |
DisclosureSEC source: 0001333277-19-000026 · edgar.xml · derivative · entry 1 Shah Sujal · CIK 0001588861 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 328,492 Underlying: Common Stock · 328,492 shares Expires 2029-01-28 F1 · derivative.exercise_date: The option vests as to 1/4 of the underlying shares on January 1, 2020, and vests as to 1/48 of the underlying shares monthly thereafter. Read SEC document |
| December 21, 2018 Filed Dec 21, 2018 17:11 UTC | CymaBay Therapeutics, Inc. CBAY · Entity 92768 | PurchaseCommon Stock | 10,000 | $6.54 | $65,399.00 |
DisclosureSEC source: 0001333277-18-000041 · edgar.xml · nonDerivative · entry 1 Shah Sujal · CIK 0001588861 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 110,000 F1 · price: The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $6.5397 to $6.54, inclusive. The reporting person undertakes to provide to CymaBay Therapeutics, Inc., any security holder of CymaBay Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document |
| October 15, 2018 Filed Oct 16, 2018 06:21 UTC | CymaBay Therapeutics, Inc. CBAY · Entity 92768 | PurchaseCommon Stock | 5,000 | $9.90 | $49,500.00 |
DisclosureSEC source: 0001333277-18-000040 · edgar.xml · nonDerivative · entry 1 Shah Sujal · CIK 0001588861 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Read SEC document |
| July 27, 2018 Filed Jul 30, 2018 06:05 UTC | CymaBay Therapeutics, Inc. CBAY · Entity 92768 | PurchaseCommon Stock | 5,000 | $10.90 | $54,500.00 |
DisclosureSEC source: 0001333277-18-000037 · edgar.xml · nonDerivative · entry 1 Shah Sujal · CIK 0001588861 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 95,000 Read SEC document |
| May 11, 2018 Filed May 15, 2018 08:08 UTC | CymaBay Therapeutics, Inc. CBAY · Entity 92768 | PurchaseCommon Stock | 5,000 | $10.65 | $53,250.00 |
DisclosureSEC source: 0001333277-18-000036 · edgar.xml · nonDerivative · entry 1 Shah Sujal · CIK 0001588861 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,000 Read SEC document |
| January 24, 2018 Filed Jan 26, 2018 17:41 UTC | CymaBay Therapeutics, Inc. CBAY · Entity 92768 | GrantEmployee Stock Option (right to buy) · Derivative | 150,000 | $0.00 Strike: $11.69 | $0.00 |
DisclosureSEC source: 0001333277-18-000030 · edgar.xml · derivative · entry 1 Shah Sujal · CIK 0001588861 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 150,000 shares Expires 2028-01-23 F1 · derivative.exercise_date: The option vests as to 1/4 of the underlying shares on January 1, 2019, and vests as to 1/48 of the underlying shares monthly thereafter. Read SEC document |
| October 27, 2017 Filed Oct 31, 2017 21:31 UTC | CymaBay Therapeutics, Inc. CBAY · Entity 92768 | GrantStock Option (right to buy) · Derivative | 640,000 | $0.00 Strike: $9.21 | $0.00 |
DisclosureSEC source: 0001209191-17-058527 · doc4.xml · derivative · entry 1 Shah Sujal · CIK 0001588861 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 640,000 Underlying: Common Stock · 640,000 shares Expires 2027-10-26 F1 · derivative.exercise_date: The shares subject to the option shall vest in 48 equal monthly installments commencing on October 27, 2017, subject to the Reporting Person's continuous service to the Issuer as of each such date. Read SEC document |
| July 20, 2017 Filed Jul 24, 2017 06:15 UTC | CymaBay Therapeutics, Inc. CBAY · Entity 92768 | PurchaseCommon Stock | 8,033 | $7.35 | $59,042.55 |
DisclosureSEC source: 0001209191-17-046040 · doc4.xml · nonDerivative · entry 5 Shah Sujal · CIK 0001588861 · Director · Interim President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,000 Read SEC document |
| July 20, 2017 Filed Jul 24, 2017 06:15 UTC | CymaBay Therapeutics, Inc. CBAY · Entity 92768 | PurchaseCommon Stock | 100 | $7.32 | $732.00 |
DisclosureSEC source: 0001209191-17-046040 · doc4.xml · nonDerivative · entry 4 Shah Sujal · CIK 0001588861 · Director · Interim President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 76,967 Read SEC document |
| July 20, 2017 Filed Jul 24, 2017 06:15 UTC | CymaBay Therapeutics, Inc. CBAY · Entity 92768 | PurchaseCommon Stock | 576 | $7.31 | $4,210.56 |
DisclosureSEC source: 0001209191-17-046040 · doc4.xml · nonDerivative · entry 3 Shah Sujal · CIK 0001588861 · Director · Interim President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 76,867 Read SEC document |
| July 20, 2017 Filed Jul 24, 2017 06:15 UTC | CymaBay Therapeutics, Inc. CBAY · Entity 92768 | PurchaseCommon Stock | 400 | $7.30 | $2,920.00 |
DisclosureSEC source: 0001209191-17-046040 · doc4.xml · nonDerivative · entry 2 Shah Sujal · CIK 0001588861 · Director · Interim President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 76,291 Read SEC document |
| July 20, 2017 Filed Jul 24, 2017 06:15 UTC | CymaBay Therapeutics, Inc. CBAY · Entity 92768 | PurchaseCommon Stock | 891 | $7.29 | $6,495.39 |
DisclosureSEC source: 0001209191-17-046040 · doc4.xml · nonDerivative · entry 1 Shah Sujal · CIK 0001588861 · Director · Interim President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,891 Read SEC document |
| April 27, 2017 Filed May 1, 2017 19:47 UTC | CymaBay Therapeutics, Inc. CBAY · Entity 92768 | GrantEmployee Stock Option (right to buy) · Derivative | 90,000 | $0.00 Strike: $3.48 | $0.00 |
DisclosureSEC source: 0001179110-17-006329 · edgar.xml · derivative · entry 1 Shah Sujal · CIK 0001588861 · Interim CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,000 Underlying: Common Stock · 90,000 shares Expires 2027-04-26 F1 · derivative.exercise_date: The option vests in equal monthly installments over the eight-month period beginning on the vesting commencement date of April 15, 2017, subject to the Reporting Person's continuous service to the Issuer. Read SEC document |
| January 19, 2017 Filed Jan 23, 2017 18:29 UTC | CymaBay Therapeutics, Inc. CBAY · Entity 92768 | GrantEmployee Stock Option (right to buy) · Derivative | 100,000 | $0.00 Strike: $1.72 | $0.00 |
DisclosureSEC source: 0001179110-17-001190 · edgar.xml · derivative · entry 1 Shah Sujal · CIK 0001588861 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2027-01-18 F1 · derivative.exercise_date: The option vests with respect to one-quarter of the underlying shares upon the first anniversary of the grant date, and then with respect to the remaining shares monthly thereafter over the next three years. Read SEC document |
| January 04, 2017 Filed Jan 6, 2017 19:31 UTC | CymaBay Therapeutics, Inc. CBAY · Entity 92768 | GrantEmployee Stock Option (right to buy) · Derivative | 25,000 | $0.00 Strike: $1.82 | $0.00 |
DisclosureSEC source: 0001179110-17-000724 · edgar.xml · derivative · entry 1 Shah Sujal · CIK 0001588861 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 25,000 shares Expires 2026-07-24 F1 · balance_after: On July 25, 2016, the Reporting Person was granted an option to purchase 50,000 shares of common stock of the Issuer. The option vests in two equal installments based on the Issuer's achieving certain milestones. The first milestone was met on December 30, 2016, resulting in vesting of the option as to 25,000 shares, which was reported on a prior Form 4. The second milestone was met on January 4, 2017, resulting in vesting of the option as to the remaining 25,000 shares. Read SEC document |
| December 30, 2016 Filed Jan 4, 2017 20:18 UTC | CymaBay Therapeutics, Inc. CBAY · Entity 92768 | GrantEmployee Stock Option (right to buy) · Derivative | 25,000 | $0.00 Strike: $1.82 | $0.00 |
DisclosureSEC source: 0001179110-17-000410 · edgar.xml · derivative · entry 1 Shah Sujal · CIK 0001588861 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2026-07-24 F1 · balance_after: On July 25, 2016, the Reporting Person was granted an option to purchase 50,000 shares of common stock of the Issuer. The option vests in two equal installments based on the Issuer's achieving certain milestones. The first milestone was met, resulting in vesting of the option as to 25,000 shares. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.